仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Nivolumab （anti-PD-1） is a genetically engineered, fully human immunoglobulin （Ig） G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 （PD-1,PCD-1） with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.